LysoPC(20:5(5Z,8Z,11Z,14Z,17Z))
|
Basic information |
| Metabolite name | LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) |
 | HMDB0010397 |
 |
C04230 |
 |
11757087 |
| Synonyms | NA |
| No. of studies | 5 |
|
Basic information |
| Metabolite name | LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) |
| HMDB0010397 |
|
C04230 |
|
11757087 |
| Synonyms | NA |
| No. of studies | 5 |
|
Relationship between LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) and depression (count: 5) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M469 | Type1 | Parkinson's disease with depression group vs. Parkinson's disease without depression group | Plasma | Human | Down |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M681 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M681 | Type2 | CUMS + Chaihu Shu Gan San group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M858 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |